Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

Goldman J. W., Garassino M. C., Chen Y., Reinmuth N., Hotta K., Poltoratskiy A., ...More

ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31, (Summary Text)

  • Publication Type: Conference Paper / Summary Text
  • Volume: 31
  • Doi Number: 10.1016/j.annonc.2020.08.2328
  • Country: ELECTR NETWORK
  • Istanbul University Affiliated: No